Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients

This study aimed to investigate the role of bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) who had developed acquired resistance to EGFR-TKIs therapy that manifested as malignant pleural effusion (MPE). In total, 86 patients were included. 47 patients received bevacizumab p...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Jiang, Tao, Li, Aiwu, Su, Chunxia, Li, Xuefei, Zhao, Chao, Ren, Shengxiang, Zhou, Caicun, Zhang, Jun
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2017
Ämnen:
Clinical Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5617537/
https://ncbi.nlm.nih.gov/pubmed/28977977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16061
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk